読み込み中
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.
最新データ
HK$3.39
+HK$0.03 · +0.89%
日中の時刻はHKTです。市場データは遅延する場合があります。
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.
日中レンジ
現在 HK$3.39
52週レンジ
現在 HK$3.39
日中の時刻はHKTです。市場データは遅延する場合があります。
HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.
日中レンジ
現在 HK$3.39
52週レンジ
現在 HK$3.39
営業利益
純利益
| 指標（CNY） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 1.64億 CNY | 3.64億 CNY | 3.12億 CNY | 1.83億 CNY | 8401.2万 CNY |
| 販売・一般管理 | 5910.2万 CNY | 8122.9万 CNY | 1.37億 CNY | 4343.3万 CNY | 4806.4万 CNY |
| 営業費用 | 2.24億 CNY | 4.45億 CNY | 4.48億 CNY | 2.26億 CNY | 1.32億 CNY |
| 受取利息 | 1022.63万 CNY | 2.76万 CNY | 2682.94万 CNY | 354.5万 CNY | 96.4万 CNY |
| 支払利息 | 230.28万 CNY | 153.4万 CNY | 44.2万 CNY | 42.6万 CNY | 452.8万 CNY |
| 減価償却費と償却費 | 625.7万 CNY | 589.6万 CNY | 182.9万 CNY | 127.4万 CNY | 159万 CNY |
| 営業利益 | −2.24億 CNY | −4.45億 CNY | −4.48億 CNY | −2.26億 CNY | −1.32億 CNY |
| 純利益 | −2.45億 CNY | −3.82億 CNY | −9.39億 CNY | −1.9億 CNY | −2.21億 CNY |
会社概要が更新されました 2026年10月9日.
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
